There’s a moment partway through a recent episode of Health Uncensored with Dr. Drew that’s hard to shake. Dr. Drew Pinsky — physician, media veteran, someone who has spent decades in rooms full of sick people — sits down and lets a phlebotomist draw his blood. Live. On camera. Not for dramatic effect, exactly, but to demonstrate something the guest across from him, a startup founder named Nate Graville, had been arguing for: that the most consequential part of modern healthcare might actually happen at home, before anything goes wrong.
The startup is Geviti, a Phoenix-based precision health company that has been building quietly — and then, lately, not so quietly. Its recent appearance on Dr. Drew’s nationally broadcast program arrived just weeks after the company launched what it describes as a first-to-market free AI platform for interpreting blood biomarker data. The timing wasn’t accidental. Geviti seems to understand that healthcare’s next real battleground isn’t treatment. It’s the conversation that happens years before treatment becomes necessary.
The pitch is deceptively simple. Most people, Graville told Dr. Drew, are already collecting health data. They wear devices on their wrists. They get annual labs. They click through wellness apps. But very few of them genuinely understand what any of it means — or whether a slightly elevated inflammatory marker combined with a subtle hormonal shift should prompt a conversation with a clinician. Geviti’s AI system is designed to catch those kinds of patterns, the ones that sit below the threshold of obvious concern but above the level of nothing to worry about.
What separates this from the usual digital health promises is the clinical backbone. Geviti isn’t offering a chatbot that reads your bloodwork and suggests more sleep. The model is hybrid — AI does the pattern recognition and scale work, while human clinicians remain at the center of care decisions. Physician-led consultations happen over Zoom. At-home phlebotomy brings the lab draw to your couch. Results get interpreted through a framework that covers more than 95 biomarkers across multiple systems, run twice a year, with the AI functioning as what Graville has called a “force multiplier” rather than a replacement.
It’s still unclear whether that distinction — AI-enhanced versus AI-driven — will matter to regulators or consumers long-term. But for now, it seems to be mattering a great deal to investors. Geviti closed an $8.5 million seed round in under a month, a pace that suggests the people writing the checks weren’t doing a lot of hand-wringing. That kind of capital velocity, in a market that has cooled considerably on speculative health tech, says something worth paying attention to.
The company has since expanded clinical operations to 47 states and introduced tiered membership options, including a Lite tier designed to lower the cost barrier to what was previously expensive longevity diagnostics. There’s a sense — watching this unfold from the outside — that Geviti is trying to solve a distribution problem as much as a technology one. The science of biomarker analysis isn’t new. Getting it to someone in rural Ohio before their first cardiac event, at a price they can afford, is the harder challenge.
The Dr. Drew segment gave the company something money can’t easily manufacture: credibility with a general audience that remains genuinely skeptical of Silicon Valley’s healthcare ambitions. Dr. Drew’s viewers aren’t early adopters hunting for the next wellness gadget. They’re people who’ve watched too many health tech promises dissolve into nothing. Earning their attention is different than earning a VC check, and probably more durable.
What Geviti is betting on — and it does feel like a real bet, not a safe one — is that enough Americans are ready to stop waiting for symptoms before engaging with their own health. The healthcare system, as it currently exists, is extremely good at managing illness. It was never designed to prevent it. Geviti isn’t the first company to notice that gap. But it may be one of the few building something that could actually fit through it.
